Evidence map›Paper›PMID 36769387›Full record

ReviewJournal of clinical medicine2023

Current Advances in Gene Therapies of Genetic Auditory Neuropathy Spectrum Disorder.

Anissa Rym Saidia, Jérôme Ruel, Amel Bahloul, Benjamin Chaix, Frédéric Venail, Jing Wang

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07778641 (Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07778641 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Genetic Study of OTOF- Related Auditory Neuropathy Spectrum Disorder

Typeobservational_patient_registrySponsorSohag UniversityRan2026 to 2027Enrolled30ConditionsAuditory Neuropathy Spectrum Disorder, Auditory NeuropathyArmsWhole exome sequencing.
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Neural Hearing Loss: Mechanisms, Diagnosis and Treatment Horizons.Journal of the Association for Research in Otolaryngology : JARO · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. A novel mutation in theIntractable & rare diseases research · 2024
    Article
  7. The human OPA1Cellular and molecular life sciences : CMLS · 2024
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anissa Rym SaidiaInstitute for Neurosciences of Montpellier (INM), University Montpellier, INSERM, 34295 Montpellier, France.ORCID 0000-0001-6038-0795
Jérôme RuelInstitute for Neurosciences of Montpellier (INM), University Montpellier, INSERM, 34295 Montpellier, France.
Amel BahloulInstitute for Neurosciences of Montpellier (INM), University Montpellier, INSERM, 34295 Montpellier, France.ORCID 0000-0001-7042-4616
Benjamin ChaixDepartment of ENT and Head and Neck Surgery, University Hospital of Montpellier, 34295 Montpellier, France.ORCID 0000-0001-5934-9774
Frédéric VenailInstitute for Neurosciences of Montpellier (INM), University Montpellier, INSERM, 34295 Montpellier, France.
Jing WangInstitute for Neurosciences of Montpellier (INM), University Montpellier, INSERM, 34295 Montpellier, France.ORCID 0000-0002-2670-719X

Funding

Fondation Gueules Cassées 65-2022Fondation Recherche Médicale REP202110014234
6 · The paper itself

Abstract

Auditory neuropathy spectrum disorder (ANSD) refers to a range of hearing impairments characterized by an impaired transmission of sound from the cochlea to the brain. This defect can be due to a lesion or defect in the inner hair cell (IHC), IHC ribbon synapse (e.g., pre-synaptic release of glutamate), postsynaptic terminals of the spiral ganglion neurons, or demyelination and axonal loss within the auditory nerve. To date, the only clinical treatment options for ANSD are hearing aids and cochlear implantation. However, despite the advances in hearing-aid and cochlear-implant technologies, the quality of perceived sound still cannot match that of the normal ear. Recent advanced genetic diagnostics and clinical audiology made it possible to identify the precise site of a lesion and to characterize the specific disease mechanisms of ANSD, thus bringing renewed hope to the treatment or prevention of auditory neurodegeneration. Moreover, genetic routes involving the replacement or corrective editing of mutant sequences or defected genes to repair damaged cells for the future restoration of hearing in deaf people are showing promise. In this review, we provide an update on recent discoveries in the molecular pathophysiology of genetic lesions, auditory synaptopathy and neuropathy, and gene-therapy research towards hearing restoration in rodent models and in clinical trials.

Indexed as

auditory neuropathyauditory synaptopathygene therapygenetic deafnesshearing restorationhidden hearing loss

Identifiers

PMID36769387
PMCPMC9918155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.